AIHTA - Publications - Search - Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC)

Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Oncology Fact Sheet Nr. 116.

[thumbnail of Oncology Fact Sheet Nr.116.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
1MB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 700-770 Liver. Billary tract
Language:English
Series Name:Oncology Fact Sheet Nr. 116
Deposited on:07 Dec 2022 01:33
Last Modified:07 Dec 2022 01:33

Repository Staff Only: item control page